In breast cancer cells, alongside the aforementioned repressive effect on cyclin D1, the expression of estrogen receptor (ER) alpha is simultaneously inhibited by ciglitazone, possibly yielding a synergistic anti-tumor effect (39, 60). Here, ESR1 is linked to breast cancer.